Springs At Watermark 3030 Park, The in Bridgeport, CT

Springs At Watermark 3030 Park, The is a medicare certified nursing home in Bridgeport, Connecticut. It is located in Fairfield county at 3030 Park Avenue, Bridgeport, Connecticut 06604. You can reach out to the office of Springs At Watermark 3030 Park, The via phone at (203) 374-5611. This skilled nursing facility has 23 federally certified beds with average occupancy rate of 64.35%. The nursing facility is classified as "Continuing Care Retirement Community" by CMS and its legal business name is Ct Watermark 3030 Llc and has the following ownership type - For Profit - Corporation.

Springs At Watermark 3030 Park, The (Medicare CCN 075440) is certified by CMS (Centers for Medicare & Medicaid Services) and participates in medicare program. This means if you are part of medicare program, you may consider this nursing facility for your medical needs. It was first certified by CMS in 2009 (15 years certified) and the last quality survey was conducted in March, 2019.

Name	Springs At Watermark 3030 Park, The
Location	3030 Park Avenue, Bridgeport, Connecticut
Certified By	Medicare
No. of Certified Beds	23
Occupancy Rate	64.35%
Medicare ID (CCN)	075440
Legal Business Name	Ct Watermark 3030 Llc
Ownership Type	For Profit - Corporation

Nursing Homes may have multiple NPI numbers. We have found possible NPI number/s associated with Springs At Watermark 3030 Park, The from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number	1275704462
Organization Name	WATERMARK 3030 PARK LLC
Doing Business As	THE SPRINGS AT WATERMARK 3030 PARK
Address	3030 Park Ave, Bridgeport, CT 06604
Phone Number	203-374-4611

News Archive

SLU professor reveals why women have higher rates of strokes than men, suggests steps to reduce risk

Each year, around 55,000 more women than men will have a stroke. Longer lifespans, pregnancies and hormones all contribute to the disparity, as do illnesses that tend to strike women more frequently. Crunch the numbers and the math adds up to more strokes for women, making it important for women monitor their risk.

KYTHERA receives U.S. patent allowance for ATX-101

KYTHERA Biopharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application that claims synthetic deoxycholic acid or pharmaceutically acceptable salts thereof, including the synthetic form that is used in ATX-101, a potential first-in-class, injectable drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin."

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy that would improve median overall survival over IFL (bolus 5-fluorouracil, generics/leucovorin, generics/irinotecan*) plus bevacizumab (Roche/Genentech/Chugai's Avastin), would earn a 60 percent patient share in stage IV colorectal cancer, according to surveyed U.S. oncologists. In Europe, such an agent would earn a 50 percent patient share, according to surveyed European oncologists.

Read more Medical News

› Verified 5 days ago

NPI Number	1720439391
Organization Name	CT WATERMARK 3030, LLC
Address	3030 Park Ave, Bridgeport, CT 06604
Phone Number	203-374-5611

News Archive

SLU professor reveals why women have higher rates of strokes than men, suggests steps to reduce risk

Each year, around 55,000 more women than men will have a stroke. Longer lifespans, pregnancies and hormones all contribute to the disparity, as do illnesses that tend to strike women more frequently. Crunch the numbers and the math adds up to more strokes for women, making it important for women monitor their risk.

KYTHERA receives U.S. patent allowance for ATX-101

KYTHERA Biopharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application that claims synthetic deoxycholic acid or pharmaceutically acceptable salts thereof, including the synthetic form that is used in ATX-101, a potential first-in-class, injectable drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin."

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy that would improve median overall survival over IFL (bolus 5-fluorouracil, generics/leucovorin, generics/irinotecan*) plus bevacizumab (Roche/Genentech/Chugai's Avastin), would earn a 60 percent patient share in stage IV colorectal cancer, according to surveyed U.S. oncologists. In Europe, such an agent would earn a 50 percent patient share, according to surveyed European oncologists.

Read more Medical News

› Verified 5 days ago

Nursing homes vary in the quality of care and services they provide to their residents. The below quality ratings for Springs At Watermark 3030 Park, The are calculated from three sources - health inspection results, staffing data, and quality measure data. This information gives you an indication of the care Springs At Watermark 3030 Park, The give to their patients.

Ratings from Surveys (Inspections):
Ratings from Quality Measures:
Ratings from Staffing Data:
Overall Rating:

News Archive

SLU professor reveals why women have higher rates of strokes than men, suggests steps to reduce risk

Each year, around 55,000 more women than men will have a stroke. Longer lifespans, pregnancies and hormones all contribute to the disparity, as do illnesses that tend to strike women more frequently. Crunch the numbers and the math adds up to more strokes for women, making it important for women monitor their risk.

KYTHERA receives U.S. patent allowance for ATX-101

KYTHERA Biopharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application that claims synthetic deoxycholic acid or pharmaceutically acceptable salts thereof, including the synthetic form that is used in ATX-101, a potential first-in-class, injectable drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin."

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy that would improve median overall survival over IFL (bolus 5-fluorouracil, generics/leucovorin, generics/irinotecan*) plus bevacizumab (Roche/Genentech/Chugai's Avastin), would earn a 60 percent patient share in stage IV colorectal cancer, according to surveyed U.S. oncologists. In Europe, such an agent would earn a 50 percent patient share, according to surveyed European oncologists.

Read more Medical News

› Verified 5 days ago

Number of Facility Reported Incidents	0
Number of Substantiated Complaints	0
Number of Fines	1
Total Amount of Fines in Dollars	$6633
Number of Payment Denials	0
Total Number of Penalties	1

The resident survey data of Springs At Watermark 3030 Park, The is compared against the national average with the color code indicators: Better than National Average Worse than National Average

Experience Measure	Provider	National Avg.